Abstract-Pharmacological studies were undertaken to clarify the profile of cis-2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl) butyl) hexahydro-1 H-isoindole-1,3-(2H)-dione hydrochloride (SM-9018), a new neuroleptic drug. SM-9018 had very high binding affinities for both 5-hydroxytryptamine2
Abstract-Pharmacological studies were undertaken to clarify the profile of cis-2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl) butyl) hexahydro-1 H-isoindole-1,3-(2H)-dione hydrochloride (SM-9018), a new neuroleptic drug. SM-9018 had very high binding affinities for both 5-hydroxytryptamine2
(5-HT2) and dopamine2 (D2) receptors, unlike many other neuroleptics.
SM-9018 also strongly inhibited 5-HT2 receptor-mediated behavior such as tryptamine-induced clonic seizure and D2 receptor-mediated behavior such as methamphetamine-induced hyperactivity, apomorphine-induced stereotypy and climbing behavior. SM-9018 possessed only a weak cataleptogenic activity, which may be clinically related to extrapyramidal side effects, despite its potent D2 antagonistic activity. Moreover, SM-9018 induced weak central depressant effects such as inhibition of spontaneous locomotor activity and motor coordination, as compared with classical neuroleptics (haloperidol and chlorpromazine).
These results suggest that SM-9018 is a new neuroleptic drug with both potent 5-HT2 and D2 antagonistic activities and with low cata leptogenic and central depressant activities.
Although neuroleptic drugs continue to represent the best form of treatment for schizophrenia, they still possess two major disadvantages.
First of all, schizophrenic patients with a preponderance of negative symptoms such as apathy and social with drawal do not respond to neuroleptic treat ment (1). Secondly, many neuroleptics pro duce extrapyramidal side effects (1).
The pharmacological blockade of central dopamine-2 (D2) receptors in limbic areas and the frontal cortex, sites of action of known neuroleptics, is held responsible for the marked control of positive symptoms (2, 3). However, this action in the striatum produces extrapyramidal side effects (4). On the other hand, the mechanism of the negative symp toms is still unclear. It has nevertheless been reported that the selective 5-hydroxytrypt amine2
(5-HT2) receptor antagonists ritanserin and setoperone ameliorate negative symptoms and reduce the incidence of ex trapyramidal side effects caused by neuro leptic maintenance therapy (5-7). Cis-2-(4-(4-(1,2-benzisothiazol-3-yl) -1 piperazinyl) butyl) hexahydro-1 H-isoindole 1,3(2H)-dione hydrochloride (SM-9018) is a new neuroleptic drug with both potent 5 HT2 and D2 antagonistic action. The chemical structure of SM-9018 differs from analogs of known antipsychotic agents such as butyro phenone, phenothiazine and benzamide deriv atives (Fig. 1) 
Materials and Methods
Male Sprague-Dawley rats (170-290 g) and male ddY mice (20-30 g) were used. All in vivo experiments were carried out in air conditioned laboratory rooms (temperature 24+1 °C, relative humidity 55±5%). 1. Biochemical studies Rats were decapitated, the brains were immediately removed, and the cortex and striatum were dissected on ice. Protein con tent of synaptic membrane preparations was determined by the method of Lowry et al. (8) . Ki values were derived from IC50 values of binding assays according to the relationship K,=1C50/(1 +S/Kd), where S is the concen tration of the radioligand and Kd is the dis sociation constant. IC50 values, which pro duce 50% inhibition of specific binding of radioligand, were constructed from Hill plots by least squares linear regression with com puter assistance. Kd values were 1.5 nM and 0.11 nM in the present binding assays using 3H-ketanserin and 3H-spiperone , respectively. 1) 3H-Ketanserin binding assay 3H-Ketanserin binding was assayed in the rat cortex membrane using a previously described method (9) with a slight modi fication. Briefly, rat cortex was homogenized in 9 volumes of ice-cold 0.32 M sucrose using a teflon-glass homogenizer and then centrifuged (700xg, 10 min, 4°C). The supernatant was suspended in 10 volumes of ice-cold 50 mM Tris-HCI buffer (pH 7.4) and centrifuged for 10 min at 43,500xg and 4°C. The pellet was resuspended in 10 volumes of the same buffer. This suspension was incu bated at 37'C for 10 min and centrifuged at 43,500 x g at 40C for 10 min. The pellet was washed twice more with 10 volumes of buffer. The resulting pellet was resuspended in buffer, and the final concentration of the suspension was adjusted to 0.5 mg protein/ml. This suspension was stored at -80°C. A 0.8-m1 portion of this membrane suspension was placed in a tube, and 0.1 ml of either test compound or vehicle was added, followed by 0.1 ml of 3H-ketanserin (77.0 Ci/mM, Amersham) at a final concentration of 1 nM. The tubes were incubated at 37°C for 30 min. Assays were carried out in triplicate. One milliliter of sample was added to 5 ml ice-cold buffer and then filtered through Whatman CF/ B glass fiber filters, which were then washed twice with 5 ml of buffer. Radioactivity trap ped on the filters was measured by liquid scintillation spectrometry. Specific binding was defined as the the excess over the non specific binding in the presence of 0.01 mM ketanserin and 20 nM prazosin required to mask 3H-ketanserin binding to alpha-1 re ceptors (10) . 2) 3H-Spiperone binding assay 3H-Spiperone binding was assayed in the rat striatum membrane using a previously described method (2) with a slight modi fication. Briefly, rat striatum was homoge nized in 20 volumes of ice-cold TEAN buffer (15 mM Tris-HCI, pH 7.5, 5 mM Na2EDTA, 0.02% (1.1 mM) ascorbate and 0.0125 mM nialamide). This homogenate was incubated at 37'C for 60 min and centrifuged at 43,500xg for 10 min, and the pellet was washed twice more with 20 volumes of the buffer. The pellet was resuspended in the buffer, and the final concentration of the suspension was adjusted to 0.5 mg protein/ ml. A 0.8-m1 portion of this membrane suspension was placed in a tube, and 0.1 ml of either test compound or vehicle was added, followed by 0.1 ml of 3H-spiperone (70.5 Ci/mM, Amersham) at a final concen tration of 0.5 nM. Tubes were incubated at 37'C for 10 min. Assays were carried out in triplicate. One milliliter of sample was added to 5 ml of ice-cold buffer, filtered through Whatman CF/B glass fiber filters, and washed twice with 5 ml of buffer. Radioactivity trap ped on the filters was measured by liquid scintillation spectrometry. Specific binding was defined as the excess over the non specific binding in the presence of 0.01 mM spiperone. 2. Behavioral studies 1) Behavioral tests related to 5-HT2 an tagonism
The method of Niemegeers et al. (11) was utilized with a slight modification. Clonic seizures in rats were observed in individual clear plastic cages (25 x 41 x 19 cm). Trypt amine (40 mg/kg) was injected intravenously into the rats 1 hr after oral administration of the test drugs.
Inhibition of tryptamine induced behavior was judged to be positive unless bilateral clonic seizures of the forepaws was observed for a period of 5 min after tryptamine injection. Six rats at each dose level were used to determine the ED50 value which decreased the incidence of clonic seizures by 50%. ED50 values were obtained from three or more doses of test drugs using the method of Litchfield and Wilcoxon (12). The same method was used to calculate the ED50 values in the following in vivo studies.
2) Behavioral tests related to D2 antagonism Methamphetamine-induced hyperactivity: The locomotor activity of rats was mea sured in individual clear plastic cages (25x 41 x 19 cm) using an Automex (Columbus Instruments). Rats were injected intraperi toneally with methamphetamine (2 mg/kg) 1 hr after oral administration of test drugs. Locomotor activity was measured for 90 min after methamphetamine injection. Six rats at each dose level were used to determine the ED50 value which produces 50% depression of methamphetamine-induced hyperactivity. Apomorphine induced stereotypy:
The method of Yamasaki et al. (13) was utilized with a slight modification. Rat stereotypy was observed in individual stainless-steel mesh cages (15x20x20 cm). Apomorphine (1.25 mg/kg) was injected intravenously 1 hr after oral administration of test drugs. Inhibition of apomorphine-induced stereotypy was judged to be positive unless stereotyped licking and biting were observed for 30 min after apomor phine injection. Six rats at each dose level were used to determine the ED50 value re quired to inhibit stereotypy by 50%.
Apomorphine-induced climbing behavior: The method of Protais et al. (14) was utilized with a slight modification. The climbing behavior of mice was observed in individual cylindrical stainless-steel wire cages (diam., 12 cm; height, 14 cm). Apomorphine (1 mg/ kg) was injected subcutaneously 1 hr after oral administration of test drugs. Climbing was observed between 10 and 20 min after apomorphine injection and was scored as fol lows: 3: pronounced, 2: moderate, 1: slight and 0: absent. Five to ten mice at each dose level were used to determine the ED50 value which reduced the climbing score by 50%.
3) Catalepsy test
The method of Yamasaki et al. (13) was utilized with a slight modification. Catalepsy in rats and mice was evaluated 1 hr after oral administration of test drugs using a horizontal bar positioned 9 cm (rats) or 5 cm (mice) above the bench. Cataleptogenic activity was judged to be positive when the forepaws of the rats and mice remained on the bar for more than 30 sec. Six rats and eight to ten mice at each dose level were used to determine the ED50 value required to induce catalepsy in 50% of the animals. 4) Behavioral tests related to alpha-1 an tagonism Norepinephrine-induced lethality: The method of Yamasaki et al. (13) was utilized with a slight modification. Rat death was ob served in individual stainless-steel mesh cages (15x20x20 cm). Norepinephrine (1.25 mg/kg) was injected intravenously 1 hr after oral administration of test drugs. Inhibition of norepinephrine-induced lethality was judged to be positive unless death was observed 30 min after norepinephrine injection. Six rats at each dose level were used to determine the ED50 value required to inhibit death by 50%.
Ptosis test: Ptosis in the mouse was ob served 1 hr after oral administration of test drugs, and was scored as follows: 4: complete closure, 3: marked closure, 2: moderate closure, 1: slight closure and 0: absent. Ptosis was judged to be positive when the mean ptosis score of both eyes was more than 2. Ten mice at each dose level were used to determine the ED50 value which induced ptosis in 50% of animals. 5) Behavioral tests related to anticholinergic action
The method of Lippmann and Pugsley (15) was utilized with a slight modification. Oxo tremorine-induced muscular tremors of mice were observed in individual clear plastic cages (12 x 12 x 18 cm). Oxotremorine (0.5 mg/kg) was injected subcutaneously 1 hr after oral administration of test drugs. Tremors were observed for 10 min after oxotremorine in jection and was scored as follows: 2: pro nounced, 1 : moderate and 0: absent. Ten mice at each dose level were used to determine the ED50 value required to reduce the tremor score by 50%. 6) Gross behavioral tests Spontaneous locomotor activity: The spontaneous locomotor activity of groups of 5 mice was measured in individual clear plastic cages (25 x 41 x 19 cm) using an Automex (Columbus Instruments). Locomo tor activity of 10 min duration was measured 1 hr after oral administration of test drugs. Ten groups of mice at each dose level were used to determine the ED50 value required to in hibit locomotor activity by 50%.
Motor coordination: Motor coordination in mice was measured using a rota-rod treadmill (Muromachi Kikai). Performance of mice on the rota-rod for 1 min was measured 1 hr after oral administration of test drugs. Inhibi tion of motor coordination was judged to be positive when the mice dropped from the rota rod in under 1 min. Ten mice at each dose level were used to determine the ED50 value re quired to inhibit motor coordination by 50%.
Potentiation of hexobarbital-induced an esthesia: Hexobarbital-induced anesthesia of mice was estimated using the duration of righting reflex loss. Hexobarbital (70 mg/kg) was injected intraperitoneally 1 hr after oral administration of test drugs. Potentiation of hexobarbital-induced anesthesia was judged to be positive when the mice lost the righting reflex for twice the mean duration of the vehicle-treated group. Ten mice at each dose level were used to determine the ED50 value which potentiated the duration of anesthesia by 50%. 3. Test compounds and reagents SM-9018, ketanserin and prazosin was synthesized in our laboratory and chlorpro mazine hydrochloride (Sigma) was obtained from a commercial source. Haloperidol (Keselan, Sumitomo), zotepine (Lodopin, Fujisawa), clocapramine (Clofekton, Yoshi tomi), thioridazine (Melleril, Sankyo), sul piride (Abilit, Sumitomo) and spiperone (Spiropitan, Eisai) were obtained by extrac tion. In the in vivo experiments, test com pounds were suspended in 0.5% methylcel lulose solution and administered orally. Trypt amine hydrochloride (Nacalai), methamphet amine hydrochloride (Dainippon), apomor phine hydrochloride (Sandoz), norepineph rine hydrochloride (Nacalai) and oxotre morine (Sigma) were dissolved in saline. Hexobarbital (Nagase) was dissolved in 0.04 N NaOH.
In the in vitro experiments, test drugs were dissolved in 1 % ethanol solution.
Results Binding affinities for 5-HT2 and D2 re ceptors:
S M-9018 concentration-depen dently inhibited the specific binding of 3H ketanserin to the 5-HT2 receptors of the synaptic membrane of rat cerebral cortex at a concentration of 0.1 to 10 nM (Fig. 2) , and the K; value was 0.613 nM. SM-9018 demon strated a very high binding affinity for 5-HT2 receptors, with a potency 6, 190 and 150 times higher than that of ketanserin, haloperi dol and chlorpromazine, respectively (Table  1) . SM-901 8 showed the highest affinity for 5-HT2 receptors of all neuroleptics tested in the present study (Table 1) .
SM-9018 also concentration-dependently inhibited specific binding of 3H-spiperone to the D2 receptors of the synaptic membrane of rat striatum at a concentration of 1 to 100 nM (Fig. 2) , with a K; value of 1.41 nM. SM-901 8 showed the highest affinity for D2 receptors of all neuroleptics studied, being slightly higher than haloperidol and 19 times higher than chlorpromazine (Table 1) . SM-9018, unlike haloperidol, chlorpro mazine and other neuroleptics, had high af finities to both 5-HT2 and D2 receptors. Of the other neuroleptics, only zotepine demon strated a similar ratio of 5-HT2: D2 binding affinity to that of SM-901 8 (Table 1) .
Antagonistic actions on 5-HT2 and D2 re ceptor-mediated behavior: SM-9018 dose dependently antagonized tryptamine-induced clonic seizures, which are regarded as being induced through 5-HT2 receptors (16) at doses of 1 to 10 mg/kg in rats; and the ED50 value of the antagonism was 1.4 mg/kg, p.o. SM-9018 was 10 and 11 times more potent than haloperidol and chlorpromazine, re spectively (Table 2) .
SM-9018 dose-dependently inhibited D2 receptor-mediated behavior such as meth amphetamine-induced hyperactivity in rats at doses of 1 to 6 mg/kg; and the ED50 value of the inhibition was 2.2 mg/kg, p.o. SM 9018 was 26% as potent as haloperidol, but eight and forty times more potent than chlorpromazine and thioridazine, respectively ( (Table 4) . SM-9018 in rats was 8% and 31 % less potent than haloperidol and chlor promazine, respectively (Table 4) . The rela tive cataleptogenic activity of SM-9018 against D2 antagonism was weaker than that of haloperidol and chlorpromazine in rats and mice and was similar to that of thioridazine in mice (Table 4) . Antagonistic actions on alpha-1 and acetyl choline receptor-mediated behavior: Ptosis induced by neuroleptics and norepinephrine induced lethality are regarded as being in duced through alpha-1 receptors (17) . SM 9018 dose-dependently antagonized nor epinephrine-induced lethality at doses of 3 to 10 mg/kg in rats, with an ED50 value of 5.1 mg/kg, p.o. SM-9018 also induced ptosis in mice with an ED50 value 19 mg/kg, p.o. SM 9018, with regard to alpha-1 antagonism against D2 antagonism, was less potent than chlorpromazine and more potent than haloperidol in both behavioral tests (Table 5) . Table 1 . Binding affinities of SM-9018 and other neuroleptics to 5-hydroxytryptamine2
(5-HT2) re ceptors and dopamine2 (D2) receptors Table 2 . Antagonism of tryptamine-induced clonic seizure and methamphetamine-induced hyperactivity in rats by SM-901 8 and other neuroleptics Table 3 . Antagonism of apomorphine-induced stereotypy in rats and climbing behavior in mice by SM 9018 and other neuroleptics dose-dependently antagonized the oxotremorine-induced tremors which are regarded as being induced through acetylcho line receptors (15) at doses of 30 to 300 mg/ kg in rats, with an ED50 value of 1 50 mg/kg, p.o. SM-9018 was four to seven times less potent than the other neuroleptics, with a weaker relative anticholinergic action against D2 antagonism than those of chlorpromazine and thioridazine (Table 6) . Central depressant action: SM-901 8 dose dependently inhibited spontaneous locomotor activity and motor coordination and also potentiated hexobarbital-induced anesthesia in mice. The ED50 values were 15, 34 and 37 mg/kg, p.o., in the inhibition of locomotion, coordination and the potentiation of anes thesia, respectively (Table 7) . However, SM 9018 was 5% and 39% as potent as haloper idol and chlorpromazine, respectively, in the spontaneous locomotor activity test of mice (Table 7) . SM-9018 showed only a weak de pressant action on the central nervous system, as compared with haloperidol and chlorpro mazine ( Table 7) .
Discussion
Unlike haloperidol, chlorpromazine and other neuroleptics, SM-9018 showed high binding affinities to both 5-HT2 and D2 re ceptors. In the 5-HT2 binding assay, SM-901 8 was 6 times more potent than the representa tive 5-HT2 antagonist ketanserin (16) , and it strongly blocked clonic seizures caused by tryptamine in rats. SM-9018 also produced potent antagonism against D2 receptor mediated behaviors. The potency of SM-9018 for blockade of methamphetamine-induced hyperactivity and apomorphine-induced stereotypy in rats was about 8 to 16 times greater than that of chlorpromazine.
Since the clinical potency of neuroleptics correlates to their D2 antagonistic activities (2), our find ings suggest that SM-901 8 would be effective for improving the positive symptoms of schizophrenia.
While we cannot rule out a potential interaction of SM-9018 with D1 receptors, our preliminary study revealed that SM-901 8 only had about 1/30 the potency in binding to D, receptors as compared with binding to D2 receptors (A. Hirose et al., unpublished data). On the other hand, 5-HT2 antagonism of drugs has been recently re ported to relate to the amelioration of negative symptoms of schizophrenia (5, 7). These findings suggest that SM-901 8 may improve not only positive but also negative symptoms.
The cataleptogenic activity of was weaker than those of haloperidol and chlorpromazine, and the relative cataleptoge nic action of SM-901 8 against D2 antagonism was similar to that of thioridazine in mice. Thioridazine is known to possess a low in cidence of extrapyramidal side effects. The lack of extrapyramidal side effects with this drug has generally been regarded as respon sible for their anticholinergic properties (18). In the present experiment, the relative an ticholinergic action of thioridazine was stronger than that of SM-9018. This result indicates that anticholinergic action is not involved in the low cataleptogenic action of SM-9018. On the other hand, degeneration of 5-HT containing neurons has been shown to de crease the cataleptogenic activity of neu roleptics (19) . Moreover, it has been reported that methysergide and cyproheptadine, which possess potent 5-HT2 antagonistic activity, inhibit haloperidol induced-catalepsy in rats (20, 21) and Parkinsonism in monkeys (22) . These findings suggest that 5-HT2 an tagonism may be related to the weak catalep togenic activity of SM-901 8. This hypothesis is supported by the clinical results that ritanserin with potent 5-HT2 antagonistic ac tivity ameliorates neuroleptic induced ex trapyramidal side effects (6, 7).
Ptosis induced by neuroleptics and nor epinephrine induced-lethality are regarded as being mediated by alpha-1 receptors (17) . Although the alpha-1 antagonistic action of SM-9018 was relatively weak as compared with its D2 and 5-HT2 antagonism, the potency of SM-9018 was between the values of chlorpromazine and haloperidol. As alpha-1 antagonism of drugs is though to relate to sedative and hypotensive actions (17) , these actions of SM-9018 were predicted to be weaker than those of chlorpromazine. On the other hand, the inhibitory action of SM-9018 on locomotor and motor coordination was weaker than that of haloperidol and chlor promazine. This result is regarded as being held responsible for the relative low catalep togenic activity of SM-9018 as opposed to the other neuroleptics.
SM-9018 had strong 5-HT2 antagonism as well as D2 antagonism, but only weak cataleptogenic and central depressant actions in animals. 
